KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Net Cash Flow (2016 - 2025)

Novavax has reported Net Cash Flow over the past 16 years, most recently at -$25.6 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$25.6 million for Q4 2025, up 21.54% from a year ago — trailing twelve months through Dec 2025 was -$295.1 million (down 860.77% YoY), and the annual figure for FY2025 was -$295.1 million, down 860.77%.
  • Net Cash Flow for Q4 2025 was -$25.6 million at Novavax, down from $13.8 million in the prior quarter.
  • Over the last five years, Net Cash Flow for NVAX hit a ceiling of $1.4 billion in Q1 2021 and a floor of -$703.5 million in Q1 2023.
  • Median Net Cash Flow over the past 5 years was -$58.7 million (2024), compared with a mean of -$19.7 million.
  • Biggest five-year swings in Net Cash Flow: surged 1214.82% in 2021 and later crashed 1390.19% in 2023.
  • Novavax's Net Cash Flow stood at -$419.5 million in 2021, then skyrocketed by 112.29% to $51.6 million in 2022, then crashed by 265.77% to -$85.5 million in 2023, then soared by 61.88% to -$32.6 million in 2024, then rose by 21.54% to -$25.6 million in 2025.
  • The last three reported values for Net Cash Flow were -$25.6 million (Q4 2025), $13.8 million (Q3 2025), and -$17.4 million (Q2 2025) per Business Quant data.